Helix CEO Dr. James Lu will be speaking about what it really takes to turn genomic data into actionable insights in everyday care – moving beyond sequencing to real-time clinical decision support, scalable infrastructure, and more equitable precision medicine.
5:00 PM Sunday, February 22, 2026
James Lu
MD, PhD, CEO and Co-Founder of Helix
Join us live for the annual American Society of Human Genetics (ASHG) conference in Montreal, Québec, CA from Oct 20-24, 2026 to learn about Helix's latest research breakthroughs in a wide range of therapeutic areas to drive precision clinical care and therapeutic development.
Join us live for the annual Festival of Genomics and Biodata conference in Boston, MA on June 3rd - 4th, 2026 to learn about how Helix is unleashing the power of clinico-genomics to support life sciences across the drug development life cycle.
Join us live at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Baltimore, MD from March 10-14, 2026 and learn about Helix's latest innovations in research.
Highlight the transformative impact of genetic testing on cardiovascular care, emphasizing the urgent need for widespread integration to improve patient outcomes, risk stratification, and personalized treatment strategies.
Address the growing importance of universal germline testing in oncology and the challenges of its widespread adoption, and why many health systems still struggle with full-scale implementation.
Metabolic Dysfunction-Associated Steatohepatitis (MASH) is becoming a leading cause of liver dysfunction, affecting over 20 million Americans. However, identifying at-risk patients and studying disease progression remains challenging. In this webinar, Dr. Cassie Hajek from Helix and Dr. Joseph Grzymski from Renown Health discuss how they're leveraging large-scale clinical and genomic data to advance MASH research.
Explore the current landscape of pharmacogenomics and its practical implementation in healthcare, with evidence on drug labels, advancing scientific understanding, and demonstrable financial benefits.
Combining clinical and genetic risk factors creates more powerful predictive models. Learn about Helix’s new prediction models for GLP-1 response and disease progression in chronic kidney disease.
Discover how targeted risk-reduction strategies after BRCA1/2 screening can significantly reduce breast cancer mortality, and learn how to close critical gaps in care through improved uptake.
Learn how combining claims data, EHR insights, and genetics can help identify high-risk patients sooner, shorten diagnostic timelines, and reduce costs by improving care for individuals with likely genetic conditions.
Helix presents research on how genetic risk for high LDL cholesterol impacts statin therapy response and cardiovascular event risk. Learn how polygenic scores could revolutionize personalized statin treatment strategies.